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ABSTRACT Hydrogen cyanide is readily detected in the headspace above Pseudomonas aeruginosa
cultures and in the breath of cystic fibrosis (CF) patients with chronic (P. aeruginosa) infection. We
investigated if exhaled breath HCN is an early marker of P. aeruginosa infection.
233 children with CF who were free from P. aeruginosa infection were followed for 2 years. Their
median (interquartile range) age was 8.0 (5.0–12.2) years. At each study visit, an exhaled breath sample
was collected for hydrogen cyanide analysis. In total, 2055 breath samples were analysed. At the end of the
study, the hydrogen cyanide concentrations were compared to the results of routine microbiology
surveillance.
P. aeruginosa was isolated from 71 children during the study with an incidence (95% CI) of 0.19
(0.15–0.23) cases per patient-year. Using a random-effects logistic model, the estimated odds ratio (95%
CI) was 3.1 (2.6–3.6), which showed that for a 1- ppbv increase in exhaled breath hydrogen cyanide, we
expected a 212% increase in the odds of P. aeruginosa infection. The sensitivity and specificity were
estimated at 33% and 99%, respectively.
Exhaled breath hydrogen cyanide is a specific biomarker of new P. aeruginosa infection in children with
CF. Its low sensitivity means that at present, hydrogen cyanide cannot be used as a screening test for this
infection.
@ERSpublications
Exhaled hydrogen cyanide is a specific but insensitive biomarker of new P. aeruginosa infection
in children with CF http://ow.ly/TdRaF
The content of this work is ©the authors or their employers. Design and branding are ©ERS 2015. This article is open
access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0
Received: July 07 2015 | Accepted after revision: Oct 02 2015
Support statement: We gratefully acknowledge the funding for the SPACE Study from a Research for Patient Benefit
Grant from the UK National Institute of Health Research (NIHR) (grant PB-PG-0909-20070). This report presents
independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of
the UK National Health Service, the NIHR or the UK Department of Health. Funding information for this article has
been deposited with FundRef.
Conflict of interest: None declared.
ERJ Open Res 2015; 1: 00044-2015 | DOI: 10.1183/23120541.00044-2015 1
ORIGINAL ARTICLE
CYSTIC FIBROSIS
Introduction
Chronic Pseudomonas aeruginosa infection has a detrimental effect on morbidity and mortality in patients
with cystic fibrosis (CF) [1, 2]. This can be prevented by early detection and treatment [3, 4]. As a
significant proportion of patients with new P. aeruginosa infection remain asymptomatic [5],
microbiological surveillance is vital to ensure that it is not missed. Unfortunately, this is difficult in
children as they are often unable or unwilling to expectorate sputum. In such patients, P. aeruginosa
detection is dependent on cough swabs, which are unreliable [6, 7]; on sputum induction, which is time
consuming and expensive [8, 9]; or on bronchoalveolar lavage (BAL), which is invasive and requires a
general anaesthetic [10]. The urgent need for a child-friendly, noninvasive method to accurately detect
P. aeruginosa infection has led to interest in developing a diagnostic exhaled breath test.
The most extensively investigated biomarker of P. aeruginosa that could be used in an exhaled breath test
is hydrogen cyanide. It has been known for more than a century that P. aeruginosa produces nonvolatile
cyanide ions [11]. More recently, selected ion flow tube mass spectroscopy (SIFT-MS) has been used to
detect and analyse volatile hydrogen cyanide released into the gas phase by cultures of P. aeruginosa [12].
The in vitro conditions affecting hydrogen cyanide release have been established [13, 14] and it is known
that P. aeruginosa is the only organism frequently found in the CF lung that produces hydrogen cyanide
[15, 16]. In vivo studies have demonstrated elevated exhaled breath hydrogen cyanide in both children and
adults with CF and chronic P. aeruginosa infection, compared to controls [17, 18]. These studies
demonstrated that hydrogen cyanide is a biomarker of chronic P. aeruginosa infection. As designed, they
could not reveal if hydrogen cyanide was an early marker of P. aeruginosa infection, which is necessary if
it is to be a used as a screening tool. The SPACE (Sensitivity and Specificity of Pseudomonas aeruginosa
Detection Using the Hydrogen Cyanide Concentration of Exhaled Breath) Study was designed to
investigate this. The aims of the SPACE Study were 1) to investigate if breath hydrogen cyanide is a
biomarker of early P. aeruginosa infection in children with CF and 2) to collect prospective data on the
incidence rate of new P. aeruginosa infection in children with CF who were previously free from
P. aeruginosa infection
Methodology
To achieve the study’s aims, exhaled breath hydrogen cyanide concentration had to be measured in a
group of children with CF around the time of a new P. aeruginosa infection. As the onset of infection
cannot be predicted, a large cohort of children who were free from P. aeruginosa infection was recruited
on the presumption that a proportion would acquire P. aeruginosa during the study. At each CF
outpatient appointment, in addition to the respiratory microbiology sample taken as part of routine care,
an exhaled breath sample was collected for hydrogen cyanide analysis and a clinical details questionnaire
completed. At the end of the study, the microbiology results were compared to the breath hydrogen
cyanide concentrations and the clinical questionnaire results.
Inclusion criteria
The inclusion criteria were: 1) children 2–16 years old with CF; 2) no P. aeruginosa isolated from the child
in the preceding 12 months; 3) all routine CF appointments at CF centres included in the SPACE Study;
and 4) all children had to be able to provide an exhaled breath sample into a collection bag.
Sample size
The power calculation was based on the expected rise in exhaled breath hydrogen cyanide concentration in
those who acquired P. aeruginosa [17]. Aiming for a sensitivity and specificity of 95%, it was estimated
that exhaled breath hydrogen cyanide concentrations needed to be measured in 46 children at the time of
P. aeruginosa infection. A retrospective audit at one of the recruiting centres found the rate of new
P. aeruginosa infections to be 0.1 cases per patient-year. The total patient-years required to originate 46
new P. aeruginosa cases was therefore estimated to be 460, which was achieved by following 230 patients
for 2 years.
Patient recruitment and follow-up
A total of 233 children were recruited from eight paediatric CF centres across the Midlands and the North
West of the UK. Their median (interquartile range (IQR)) age was 8.0 (5.0–12.2) years. At each centre,
recruitment was open for 6 months but the study start date varied between centres for administrative
reasons. The first child was recruited in June 2011 and the last child in October 2012. The study closed at
all centres in December 2013. The median duration of follow-up was 2.0 (1.7–2.3) years. 10 children were
withdrawn from the study prior to the close date: six transitioned to adult services and four moved to a
different area. The data on these 10 children are included in the analysis up to the point at which they
were withdrawn.
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Collection and analysis of breath samples
At each study visit, the children were invited to inflate a 1-L gas sampling bag made from 70-μm-thick
Nalophan using one long exhalation. Some younger children needed two or three exhalations. Once the
bag was filled, the disposable mouthpiece was removed and the bag sealed. The samples were transported
to Keele University (Keele, UK) for analysis using a Profile 3 SIFT-MS instrument (Trans Spectra Limited,
Newcastle-under-Lyme, UK) [19, 20]. The bags were punctured with a hypodermic needle directly
attached to the heated input arm of the SIFT-MS instrument. This enabled the exhaled breath gas to flow
unhindered into the analytical region of the instrument. The mean concentrations of water vapour and
hydrogen cyanide were analysed over 100 s while operating the instrument in the multiple ion monitoring
mode [21]. Informed by previous studies, the bags/samples were heated to 37°C prior to analysis, which
was carried out within 24 h of the sample being collected [22, 23]. In total, 2055 breath samples were
analysed. On eight occasions, a child refused to provide a breath sample, and on 23 occasions, the breath
sample was not analysed within 24 h due to problems with transport or with the SIFT-MS instrument.
Study visits
There was a total of 2086 study visits; the median (IQR) number of visits per patient-year was 4.8
(3.1–5.6). In addition to the breath sample, a clinical details questionnaire was completed by the child/
parent at each study visit. This collected data on the child’s general state of health, and any change in
cough, sputum production, shortness of breath or exercise tolerance. A respiratory microbiology sample
was also taken at each study visit as part of the child’s normal CF care. A sputum sample was taken from
children who were able to expectorate and a cough swab was taken from those unable to expectorate.
Induced sputum and BAL samples were not part of the study protocol, and no microbiology samples were
taken at the request of the SPACE Study team. Despite this, if such samples were taken at the request of
the clinical team, the results were included in the study analysis. To eliminate any bias by knowing from
which children P. aeruginosa had been isolated, the SPACE Study team was only informed of any positive
culture results at the end of the study.
Statistical analysis
The data are presented as median (IQR) values. The Mann–Whitney U-test was used to assess the
difference between two groups and the Kruskal–Wallis test was used when there were more than two
groups. The P. aeruginosa incidence rates (reported as cases per patient-year) were calculated as
numerator/denominator. The numerator was the number of children with a new isolate of P. aeruginosa
during the study period and the denominator was the “person-time at risk”. The person-time at risk was
the sum of the time from recruitment to the new P. aeruginosa isolate for those who isolated PA and the
total follow-up time for those who remained P. aeruginosa infection free. The Poisson 95% confidence
interval was calculated for the incidence rates and the Chi-squared test was used to compare the
significance of two incidence rates. A p-value of <0.05 was deemed significant.
Given the repeated-measures nature of the data, a random-effects logistic model was used to account for
the dependency between multiple observations from the same patient. As a guide to the estimated
sensitivity and specificity, we dichotomised the predicted probabilities using a cut-off value of 0.5 and then
estimated these quantities for clustered data [24]. The area under the receiver operator characteristics
(ROC) curve was estimated using the clustered option in the SomersD option in STATA (StataCorp,
College Station, TX, USA). To our knowledge, there is no standard method for calculating the Youden
index for correlated data and it was therefore not possible to define the optimal cut-off hydrogen cyanide
concentration that predicted P. aeruginosa infection.
Ethical approval
Ethical approval for the SPACE Study was granted by the Coventry and Warwickshire Research and Ethics
Committee (ref. 10/H1211/48).
Role of funding source
The study sponsor had no role in the collection, analysis or interpretation of data; in the writing of the
report; or in the decision to submit the paper for publication.
Results
P. aeruginosa status
None of the children recruited into the study had P. aeruginosa isolated from their sample for
⩾12 months. They were further separated into three groups according to their P. aeruginosa status: 113
children had never had P. aeruginosa grown from their samples (Never group), 99 had last P. aeruginosa
isolated from their samples >12 months ago and were not receiving nebulised anti-P. aeruginosa therapy at
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study entry (Free From (FF) group), and 21 had last had P. aeruginosa isolated from their samples
>12 months ago but had continued to receive prophylactic nebulised anti-P. aeruginosa therapy (Free
From But Treated (FFT) group). All those in the FFT group had previously been diagnosed with chronic
P. aeruginosa infection according to standard criteria [25]. The median age was lowest in the Never group
and highest in the FFT group (table 1).
Incidence of new P. aeruginosa isolates
P. aeruginosa was isolated from 71 children during the study (29 in the Never group, 31 in the FF group
and 11 in the FFT group). The median (IQR) recruitment ages were similar for those who subsequently
grew P. aeruginosa and for those who remained P. aeruginosa infection free: 7.7 (4.4–12.4) versus 8.2
(5.1–12.1) years, respectively (p=0.71). The overall incidence (95% CI) of new P. aeruginosa isolates was
0.19 (0.15–0.23) cases per patient-year. The incidence rate (95% CI) was higher in the FFT group than in
the Never and FF groups combined: 0.41 (0.20–0.73) versus 0.17 (0.14–0.22) cases per patient-year,
respectively (Chi-squared 7.41, p=0.007) (table 1). The percentage of patients remaining P. aeruginosa
infection free at the study end was 74% in the Never group, 69% in the FF group and 48% in the FFT
group (figure 1).
Recruiting centres
Table 2 shows the study activity and P. aeruginosa incidence rates in the eight centres. As we were
comparing the incidence rate of new P. aeruginosa infection between centres, we excluded children in the
FFT group as they had all previously been diagnosed with chronic P. aeruginosa infection and may only
have been culture negative due to nebulised anti-P. aeruginosa prophylaxis. The proportion of children
remaining P. aeruginosa free at the study end varied from 56% (centre 3) to 83% (centre 7). Centre 4 had
less frequent routine outpatient appointments and, therefore, a lower number of study visits per
patient-year.
Pairing of study visits and P. aeruginosa culture results
57 of the 71 children from whom P. aeruginosa was isolated had a study visit (with completed clinical
details questionnaire and an analysed breath sample) on the day of the positive P. aeruginosa culture. In
the remaining 14 children, the sample from which P. aeruginosa was isolated was not taken at a study
visit; eight were postal samples, four were taken at an unscheduled hospital visit and two took place at
visits of which the study team were unaware. In these 14 children, the gap between the positive culture
and the next study visit was 1–5 weeks, and so the breath analysis and symptom questionnaire data were
not used in the subsequent analysis.
Symptoms at the time of P. aeruginosa isolation
33 (58%) out of 57 children were symptomatic at the time of P. aeruginosa isolation. Of these, 30 (91%)
had increased cough, 16 (48%) had increased sputum volume, nine (27%) had increased shortness of
breath and seven (21%) had reduced exercise tolerance. Only 12 (36%) symptomatic children were
described as “unwell” or “less well than normal”.
TABLE 1 Pseudomonas aeruginosa incidence rates, study activity and age according to
P. aeruginosa status
P. aeruginosa
status
Recruits Age years
median (IQR)
Study activity P. aeruginosa incidence
cases per patient-year
(95% CI)
Total
visits
Visits per
patient-year
median (IQR)
Never 113 6.4 (4.0–10.9) 962 4.5 (3.1–5.4) 0.15 (0.10–0.22)
FF 99 8.1 (5.3–12.5) 910 5.0 (3.7–5.6) 0.19 (0.13–0.27)
FFT 21 13.1 (10.6–15.5) 214 5.9 (3.2–6.5) 0.41 (0.20–0.73)
Total 233 8.0 (5.0–12.2) 2086 4.8 (3.1–5.6) 0.19 (0.15–0.23)
Data are presented as n unless otherwise stated. IQR: interquartile range; FF: Free From; FFT: Free From
But Treated.
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Breath hydrogen cyanide concentrations
At the first study visit, there was no difference in the median (IQR) exhaled breath hydrogen cyanide
concentrations in parts per billion by volume (ppbv) between the three P. aeruginosa status groups: Never,
2.2 (1.3–3.2); FF, 2.3 (1.5–3.0); and FFT 2.4 (1.2–3.5) ppbv (p=0.58). The 162 children who remained
P. aeruginosa free throughout the study provided 1398 breath samples (figure 2). The median hydrogen
cyanide concentration was 2.3 (1.3–3.0) ppbv. The median (IQR) difference between an individual’s
minimum and maximum hydrogen cyanide concentration (intrasubject variation) was 2.8 (1.9–3.5) ppbv.
The hydrogen cyanide concentration on the day of P. aeruginosa isolation is shown in figure 3 for the 57
children included in this analysis. The first peak of this bimodal distribution contains breath samples from
29 patients and has a median hydrogen cyanide concentration of 2.2 ppbv. This has a similar distribution
to that seen in the P. aeruginosa negative patients in figure 2. The second peak contains breath samples
from 28 patients and has a median hydrogen cyanide concentration of 6.3 ppbv. All the breath samples in
this second peak had a hydrogen cyanide concentration >5.0 ppbv. There was no significant difference
between the children in the first and second peaks in terms of age or P. aeruginosa status. Five of the 28
children in the second peak had a hydrogen cyanide concentration ⩾5.0 ppbv for up to two visits prior to
the date of the positive P. aeruginosa culture and the hydrogen cyanide remained >5.0 ppbv in eight
children for up to two visits after the positive P. aeruginosa culture date.
Modelling longitudinal hydrogen cyanide concentration
A random-effects logistic model was used to account for the dependency between multiple observations
from the same patient. The estimated odds ratio (95% CI) was 3.12 (2.58–3.56), which showed that for a
1-ppbv increase in exhaled breath hydrogen cyanide, we expected a 212% increase in the odds of
P. aeruginosa infection. The estimated sensitivity (95% CI) was 33% (22–44%) and the estimated
FIGURE 1 Kaplan–Meier curve
showing the proportion of children
remaining free from Pseudomonas
aeruginosa infection during the study
period for each P. aeruginosa status
group. FF: Free From; FFT: Free
From But Treated.
0
10
20
30
40
50
60
70
80
90
100
0 30252015105 35
Never
FF
FFT
Time months
Ch
ild
re
n 
fr
ee
 fr
om
 P
se
ud
om
on
as
ae
ru
gi
no
sa
 in
fe
ct
io
n 
%
TABLE 2 Pseudomonas aeruginosa incidence rates, study activity and age according to
recruiting centre
Centre Recruits Age years
median (IQR)
Study activity P. aeruginosa incidence cases
per patient-year (95% CI)
Total
visits
Visits per patient
year median (IQR)
1 24 7.6 (4.0–8.0) 188 5.7 (5.3–6.3) 0.22 (0.10–0.40)
2 34 8.8 (6.0–12.0) 348 4.9 (4.3–5.2) 0.18 (0.10–0.29)
3 21 6.9 (4.9–13.2) 193 4.2 (3.5–4.5) 0.27 (0.15–0.43)
4 53 9.1 (5.4–12.5) 229 2.4 (1.9–2.8) 0.20 (0.12–0.29)
5 30 9.4 (6.7–12.9) 306 5.2 (4.5–5.5) 0.13 (0.07–0.25)
6 18 8.0 (2.4–10.7) 136 4.5 (3.7–5.3) 0.28 (0.14–0.49)
7 36 5.2 (3.3–8.5) 477 5.9 (5.2–6.7) 0.08 (0.04–0.18)
8 17 8.4 (5.2–12.0) 209 5.5 (4.9–6.2) 0.22 (0.10–0.40)
Total 233 8.0 (5.0–12.2) 2086 4.8 (3.1–5.6) 0.17 (0.14–0.22)
Data are presented as n unless otherwise stated. Children in the Free From But Treated group were
excluded when the P. aeruginosa incidence and antibiotic courses were calculated. IQR: interquartile
range.
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specificity (95% CI) was 99% (99.2–99.9%). The area under the ROC curve was estimated as 0.88
(0.83–0.94). This equates to the probability that a child with a new P. aeruginosa infection will have higher
breath hydrogen cyanide than one who remains free from P. aeruginosa.
Discussion
The SPACE Study is one of the largest breath analysis studies to be undertaken and is the first to
investigate whether exhaled breath hydrogen cyanide can be used as an early biomarker of P. aeruginosa
infection in children with CF. As well as demonstrating that hydrogen cyanide is a specific biomarker of
P. aeruginosa infection, it has provided novel prospective data on the incidence of new P. aeruginosa
infection in children previously free from P. aeruginosa infection.
The high specificity with which elevated exhaled breath hydrogen cyanide indicates early P. aeruginosa
infection is very encouraging and suggests that it may have a role in the identification of this infection. It
must also be recognised that this study did not routinely use BAL culture, which is the gold standard
method of P. aeruginosa detection in nonexpectorating patients. We therefore relied on cough swabs,
which only have a sensitivity of 44–82% [6, 7]. It is of particular interest that five children had breath
hydrogen cyanide >5.0 ppbv for one or two study visits prior to the date of their positive P. aeruginosa
culture. Although this is only a small number of children, it shows that in certain situations, exhaled
breath hydrogen cyanide may indicate the presence of P. aeruginosa infection that has been missed on
routine microbiology samples.
The low sensitivity with which elevated exhaled breath hydrogen cyanide predicted P. aeruginosa infection
was ultimately disappointing. The hydrogen cyanide concentrations at the time of P. aeruginosa isolation
showed a bimodal distribution (figure 3). The distribution of the first peak was very similar to that seen in the
children who remained free from P. aeruginosa throughout the study (figure 2). This suggests that in
approximately half of the children with a new P. aeruginosa isolate, there was little effect on their exhaled
FIGURE 2 Histogram showing the
breath hydrogen cyanide
concentrations in samples taken
from children who remained free
from Pseudomonas aeruginosa
throughout the study. The dashed
line represents the polynomial trend.
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FIGURE 3 Histogram showing the
bimodal distribution of breath
hydrogen cyanide concentrations
taken from children at the time of
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The dashed line represents the
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breath hydrogen cyanide. There are a number of possible explanations for this. One factor is the genotype of
the infecting P. aeruginosa. Our in vitro studies have shown that P. aeruginosa releases hydrogen cyanide into
the gas phase, which is detectable in the culture headspace [12]. When multiple P. aeruginosa genotypes were
analysed, they all produced hydrogen cyanide but there was a >700-fold difference in the maximum hydrogen
cyanide concentration produced by the various strains [13]. Although the exact correlation between the in
vitro headspace concentrations and the in vivo exhaled breath hydrogen cyanide concentrations is
contentious, it is reasonable to presume that pulmonary infection with one of the low hydrogen cyanide
producing strains may not produce enough hydrogen cyanide to be detected in exhaled breath.
Another factor that may lead to low sensitivity is the methodology of the hydrogen cyanide analysis. The
SPACE Study involved the analysis of breath samples taken at multiple CF centres spread over a wide
geographic area. Therefore, the only practical solution was to collect the breath samples in bags and
transport them to the SIFT-MS instrument at Keele University for analysis. When bag samples are
pre-warmed to 37°C and analysis occurs within 24 h of collection, there is good correlation between these
“offline” hydrogen cyanide concentrations and the “online” results obtained by the individual breathing
directly into the SIFT-MS instrument [22]. Despite the good correlation, offline concentrations are lower,
which increases the chance of false-negative measurements. The technology to allow accurate hydrogen
cyanide analysis at even lower concentrations, and the use of smaller and more portable devices continues to
improve. This raises the possibility of being able to take regular online measurements in the outpatient clinic.
As with all breath trace gas metabolites, there is intrasubject variation in exhaled breath hydrogen cyanide
concentrations [17]. Factors that contribute to this include diet and the time of day the sample is taken [26].
Although the children in the SPACE study were requested not to eat or drink for 30 min prior to providing
an exhaled breath sample, it was not possible to accurately confirm this and due to the different timings of
the CF clinics, it was not possible to standardise the sample time. Other factors that may have affected the
sensitivity are the use of mouth-exhaled rather than nose-exhaled breath samples and the effect of younger
children using multiple exhalations to fill the bag [18, 27].
Although the UK CF Trust Patient Registry provides data on the prevalence of chronic P. aeruginosa
infection, it does not provide data on the incidence of new P. aeruginosa infection. We believe that the SPACE
Study is the first to provide this data. Interesting differences were seen between the P. aeruginosa status groups
and the different centres. The higher incidence of new P. aeruginosa infection in the FFT group compared to
the Never and FF groups is not surprising since these children had all been started on long-term nebulised
anti-P. aeruginosa treatment after being diagnosed with chronic P. aeruginosa infection. It is generally
assumed that once chronic P. aeruginosa infection is confirmed, the organism will continue to be isolated
from the patient [28]. The results in the FFT group demonstrate that when such patients are commenced on
nebulised anti-P. aeruginosa treatment, suppression of the infection may result in P. aeruginosa not being
isolated for long periods. Therefore, these patients no longer meet the criteria for chronic P. aeruginosa
infection. How they should be classified on national databases is also open to debate. We were interested in
further investigating the variation in P. aeruginosa incidence rates between the centres. The exact infection
control practice at each centre was clarified but no single practice could be found to explain the difference in
P. aeruginosa incidence rates. Other factors that may have influenced the incidence rates include the number
of patients at each centre, the age of the patients, the model of care at each centre, the severity of the
children’s lung disease, and the social interaction and behaviour of the patients and their families.
Summary
This study has demonstrated that exhaled hydrogen cyanide is a specific biomarker of new P. aeruginosa
infection in children with CF. Its low sensitivity means that at present, hydrogen cyanide cannot be used
as a screening test for early P. aeruginosa infection. With continued advances in the sensitivity of SIFT-MS
technology, and the development of smaller and more portable instruments, this may change in the future.
The SPACE Study has also provided novel prospective data on the incidence of new P. aeruginosa
infection, which may prompt further research on infection control measures and help inform the design of
future trials, particularly in relation to P. aeruginosa eradication.
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